Phospho-Mre11 (Ser676) Antibody

• 产品编号：CST-4859S      品牌：CST       原厂货号：4859S
• 产品分类：抗体 > 一抗 > 磷酸化抗体
• 应用分类：

描述：

Phospho-Mre11 (Ser676) Antibody能够检测内源性丝氨酸（676位点）磷酸化的Mrell蛋白。该多克隆抗体是由合成的人源的针对 Mre11蛋白丝氨酸(676位)的肽段免疫动物，利用A蛋白和多肽亲和层析方法纯化生产的。Mre11最初在酿酒酵母(其突变体在减数分裂重组过程中是有缺陷的)的基因筛选中被描述(1)，它是多亚基核酸酶(MRN，由Mre11, Rad50和Nbs1组成)的关键组成部分(2,3)。MRN复合体在感知、处理和修复DNA双链断裂过程中起重要作用。其缺陷会导致基因组不稳定，端粒缩短，减数分裂异常和过敏性DNA损伤(4)。在共济失调毛细血管扩张疾病(ATLD)中已经发现了Mre11的亚等位基因突变，其表型类似于引起共济失调毛细血管扩张症(A-T)的来自ATM的突变，包括人类恶性肿瘤的易感性(5)。ATLD带来的细胞水平的不良后果主要有染色体不稳定性和响应DNA损伤的内-S期和G2/M期检验点缺陷。MRN复合体能够直接激活DNA断裂的ATM检验点激酶(6)。Phospho-Mre11 (Ser676) Antibody 作用位点是基于 PhosphoScan®和CST's LC-MS/MS 修饰位点发现平台，由Cell Signaling Technology (CST)公司鉴定的。采用ATM/ATR底物抗体能够发现676位丝氨酸的磷酸化，紫外处理能够诱导该磷酸化的发生。更多信息请访问CST修饰位点知识据库（PhosphoSitePlus®），网址为www.phosphosite.org 。

1. Ajimura, M. et al. (1993) Genetics 133, 51-66.
2. D'Amours, D. and Jackson, S.P. (2002) Nat. Rev. Mol. Cell Biol. 3, 317-327.
3. van den Bosch, M. et al. (2003) EMBO Rep. 4, 844-849.
4. Theuissen, J.F. et al. (2003) Mol. Cell 12, 1511-1523.
5. Stewart, G.S. et al. (1999) Cell 99, 577-587.
6. Carson, C.T. et al. (2003) EMBO J. 22, 6610-6620.
7. Stokes, M.P. et al. (2007) Proc. Natl. Acad. Sci. USA 104, 19855-19860.

原厂资料：

Homology

Species predicted to react based on 100% sequence homology: Monkey

Specificity / Sensitivity

Phospho-Mre11 (Ser676) Antibody detects endogenous levels of Mre11 only when phosphorylated at Ser676.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser676 of human Mre11. Antibodies are purified by protein A and peptide affinity chromatography. 

Background

Mre11, originally described in genetic screens from the yeast Saccharomyces cerevisiae in which mutants were defective in meiotic recombination (1), is a central part of a multisubunit nuclease composed of Mre11, Rad50 and Nbs1 (MRN) (2,3). The MRN complex plays a critical role in sensing, processing and repairing DNA double strand breaks. Defects lead to genomic instability, telomere shortening, aberrant meiosis and hypersensitivity to DNA damage (4). Hypomorphic mutations of Mre11 are found in ataxia-telangiectasia-like disease (ATLD), with phenotypes similar to mutations in ATM that cause ataxia-telangiectasia (A-T), including a predisposition to malignancy in humans (5). Cellular consequences of ATLD include chromosomal instability and defects in the intra-S phase and G2/M checkpoints in response to DNA damage. The MRN complex may directly activate the ATM checkpoint kinase at DNA breaks (6).

Phospho-Mre11 (Ser676) Antibody is directed to a site that was identified at Cell Signaling Technology (CST) using PhosphoScan®, CST's LC-MS/MS platform for modification site discovery. Phosphorylation at Ser676 was discovered using an ATM/ATR substrate antibody and was shown to be induced by UV treatment (7). Please visit PhosphoSitePlus®, CST's modification site knowledgebase, at www.phosphosite.org for more information.

1. Ajimura, M. et al. (1993) Genetics 133, 51-66.
2. D'Amours, D. and Jackson, S.P. (2002) Nat. Rev. Mol. Cell Biol. 3, 317-327.
3. van den Bosch, M. et al. (2003) EMBO Rep. 4, 844-849.
4. Theuissen, J.F. et al. (2003) Mol. Cell 12, 1511-1523.
5. Stewart, G.S. et al. (1999) Cell 99, 577-587.
6. Carson, C.T. et al. (2003) EMBO J. 22, 6610-6620.
7. Stokes, M.P. et al. (2007) Proc. Natl. Acad. Sci. USA 104, 19855-19860.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM
NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C.
Do not aliquot the antibody.